Behrens Hannah M, Six Anne, Walker Daniel, Kleanthous Colin
Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, U.K.
Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, U.K.
Emerg Top Life Sci. 2017 Apr 21;1(1):65-74. doi: 10.1042/ETLS20160016.
The growing incidence of antibiotic-resistant Gram-negative bacterial infections poses a serious threat to public health. Molecules that have yet to be exploited as antibiotics are potent protein toxins called bacteriocins that are produced by Gram-negative bacteria during competition for ecological niches. This review discusses the state of the art regarding the use for therapeutic purposes of two types of Gram-negative bacteriocins: colicin-like bacteriocins (CLBs) and tailocins. In addition to in vitro data, the potency of eight identified CLBs or tailocins has been demonstrated in diverse animal models of infection with no adverse effects for the host. Although the characteristics of bacteriocins will need further study, results obtained thus far regarding their in vivo potency, immunogenicity and low levels of resistance are encouraging. This leads the way for the development of novel treatments using bacteriocins as protein antibiotics.
革兰氏阴性菌对抗生素耐药性的日益增加对公众健康构成了严重威胁。尚未被用作抗生素的分子是一类名为细菌素的强效蛋白质毒素，它们由革兰氏阴性菌在争夺生态位的过程中产生。本综述讨论了两类革兰氏阴性细菌素（类大肠杆菌素细菌素和尾噬菌体素）用于治疗目的的研究现状。除了体外数据外，在多种感染动物模型中已证明了8种已鉴定的类大肠杆菌素细菌素或尾噬菌体素的效力，且对宿主无不良影响。尽管细菌素的特性还需要进一步研究，但目前关于其体内效力、免疫原性和低耐药水平的研究结果令人鼓舞。这为开发以细菌素作为蛋白质抗生素的新型治疗方法铺平了道路。
